Sfoglia per Autore
Pharmacology and clinical toxicity of 4'-Iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase 1 trials
1990 L. Gianni, L. Vigano', A. Surbone, D. Ballinari, P. Casali, C. Tarella, J. Collins, G. Bonadonna
Chemioterapia adiuvante del carcinoma del colon-retto
1990 P. Casali, L. Licitra, E. Alafaci, L. Gennari
Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas
1993 P. Casali, U. Pastorino, A. Azzarelli, R. Bertulli, P. Zucchinelli, L. Devizzi, A. Santoro
Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities
1993 A. Azzarelli, V. Quagliuolo, P. Casali, S. Fissi, F. Montalto, A. Santoro
Objective and rational evaluation of the quality of life in oncology in the first phase of the QVONC project
1997 M. Costantini, E. Mencaglia, P. Di Giulio, E. Cortesi, F. Roila, E. Ballatori, M. Tamburini, P. Casali, L. Licitra, B. Massidda, M. Luzzani, E. Campora, S. De Placido, S. Palmeri, M.A. Palladino, G. Baracco, R. Gareri, A. Martignetti, S. Ragosa, L. Zoda, M.T. Lonta, S. Bulletti, L. Pastore
Quality of life assessment and clinical decision-making
1997 P. Casali, L. Licitra, M. Costantini, A. Santoro, P. Viterbori, E. Bajetta, P. Bruzzi
START: A European state-of-the-art on-line instrument for clinical oncologists
1999 P. Casali, L. Licitra, T. C., F. De Braud, B. P., C. A., F. Cavalli
Cancer patients as 'experts' in defining quality of life domains. A multicentre survey by the Italian Group for the Evaluation of Outcomes in Oncology (IGEO)
2000 M. Costantini, E. Mencaglia, P.D. Giulio, E. Cortesi, F. Roila, E. Ballatori, M. Tamburini, P. Casali, L. Licitra, D.D. Candis, B. Massidda, M. Luzzani, E. Campora, S.D. Placido, S. Palmeri, P.M. Angela, G. Baracco, R. Gareri, A. Martignetti, S. Ragosa, L. Zoda, M.T. Ionta, S. Bulletti, L. Pastore
QUOROM and the search for an updated 'clinical method' in the era of evidence-based medicine
2000 P.G. Casali, L. Licitra, P. Bruzzi
Gastrointestinal stromal tumors: should they be treated with the same sistemic chemotherapy as other soft tissue sarcomas?
2003 T. De Pas, P. Casali, S. Toma, A. Romanini, B. Massidda, A. Comandone, R. Labianca, C. Massacesi, A. Tucci, M. Antimi, G. Biasco, M. Agliettaq, G. Apice, F. de Braud
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial
2004 J. Verweij, P.G. Casali, J. Zalcberg, A. Lecesne, P. Reichardt, J. Blay, R. Issels, A. Van Oosterom, P.C.W. Hogendoorn, M. Van Glabbeke, R. Bertulli, I. Judson
Imatinib mesylate in chordoma
2004 P.G. Casali, A. Messina, S. Stacchiotti, E. Tamborini, F. Crippa, A. Gronchi, R. Orlandi, C. Ripamonti, C. Spreafico, R. Bertieri, R. Bertulli, M. Colecchia, E. Fumagalli, A. Greco, F. Grosso, P. Olmi, M.A. Pierotti, S. Pilotti
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient
2004 E. Tamborini, L. Bonadiman, A. Greco, V. Albertini, T. Negri, A. Gronchi, R. Bertulli, M. Colecchia, P.G. Casali, M.A. Pierotti, S. Pilotti
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
2006 G.D. Demetri, A.T. van Oosterom, C.R. Garrett, M.E. Blackstein, M.H. Shah, J. Verweij, G. Mcarthur, I.R. Judson, M.C. Heinrich, J.A. Morgan, J. Desai, C.D. Fletcher, S. George, C.L. Bello, X. Huang, C.M. Baum, P.G. Casali
The off-label use of drugs in oncology: A position paper by the European Society for Medical Oncology (ESMO)
2007 P.G. Casali
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
2007 F. Grosso, R.L. Jones, G.D. Demetri, I.R. Judson, J. Blay, A. Le Cesne, R. Sanfilippo, P. Casieri, P. Collini, P. Dileo, C. Spreafico, S. Stacchiotti, E. Tamborini, J.C. Tercero, J. Jimeno, M. D'Incalci, A. Gronchi, J.A. Fletcher, S. Pilotti, P.G. Casali
A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake
2007 D. Mannavola, P. Coco, G. M. Vannucchi, R. Bertuelli, M. Carletto, P.G. Casali, P. Beck-Peccoz, L. Fugazzola
Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient [3]
2007 T. Negri, P. Casieri, F. Miselli, M. Orsenigo, C. Piacenza, S. Stacchiotti, P. Bidoli, P.G. Casali, M.A. Pierotti, E. Tamborini, S. Pilotti
Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate
2008 H. Joensuu, F. De Braud, P. Coco, T. De Pas, C. Putzu, C. Spreafico, P. Bono, S. Bosselli, T. Jalava, D. Laurent, P. Casali
Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors?
2008 F. Miselli, T. Negri, A. Gronchi, M. Losa, E. Conca, S. Brich, E. Fumagalli, M. Fiore, P.G. Casali, M.A. Pierotti, E. Tamborini, S. Pilotti
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile